Switzerland's Basilea revenue rises 11% on Cresemba demand

Basilea Pharmaceutica AG, Allschwil

17/02/2026 06:22

Overview

Swiss biopharma's 2025 revenue rose 11%, driven by strong Cresemba demand

Royalty income increased 15% due to Cresemba's market demand

Net cash position tripled, supporting R&D and growth initiatives

Outlook

Company expects FY 2026 total revenue to increase by ~10%

Basilea projects FY 2026 operating profit to rise by ~20%

Company plans significant R&D investment in fosmanogepix and ceftibuten-ledaborbactam

Result Drivers

CRESEMBA DEMAND - Strong demand for Cresemba drove a 15% increase in royalty income

R&D INVESTMENT - Significant R&D investment focused on fosmanogepix phase 3 studies and ceftibuten-ledaborbactam in-licensing

CASH POSITION - Tripled net cash position supports R&D and growth initiatives

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
CHF 3.14
FY Net Income
CHF 40.20 mln
FY Basic EPS
CHF 3.29
FY Operating Expenses
-CHF 180.80 mln
FY Operating Income
CHF 51.50 mln
FY Pretax Profit
CHF 45.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Basilea Pharmaceutica AG Allschwil is CHF105.00, about 88.5% above its February 16 closing price of CHF55.70

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNE7Jj3gg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)